Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Joey A. Jacobs purchased 3,708 shares of the business’s stock in a transaction on Thursday, April 25th. The shares were acquired at an average price of $6.15 per share, for a total transaction of $22,804.20. Following the completion of the purchase, the director now directly owns 75,016 shares of the company’s stock, valued at $461,348.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
NASDAQ:CPIX traded down $0.17 on Friday, reaching $5.78. 1,137 shares of the company’s stock were exchanged, compared to its average volume of 8,674. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.13 and a quick ratio of 1.69. The firm has a market capitalization of $91.91 million, a PE ratio of -48.17 and a beta of 0.31. Cumberland Pharmaceuticals, Inc. has a 52-week low of $4.83 and a 52-week high of $7.00.
Cumberland Pharmaceuticals (NASDAQ:CPIX) last issued its quarterly earnings results on Tuesday, February 26th. The specialty pharmaceutical company reported $0.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.24. The company had revenue of $13.50 million for the quarter, compared to analyst estimates of $10.98 million. Cumberland Pharmaceuticals had a negative net margin of 17.09% and a negative return on equity of 3.08%. Analysts expect that Cumberland Pharmaceuticals, Inc. will post -0.24 EPS for the current fiscal year.
Separately, TheStreet upgraded shares of Cumberland Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, April 10th.
An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Stonepine Capital Management LLC grew its holdings in shares of Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) by 1.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,218,401 shares of the specialty pharmaceutical company’s stock after purchasing an additional 15,062 shares during the period. Cumberland Pharmaceuticals comprises about 4.1% of Stonepine Capital Management LLC’s portfolio, making the stock its 9th biggest position. Stonepine Capital Management LLC owned about 7.85% of Cumberland Pharmaceuticals worth $6,957,000 at the end of the most recent quarter. 32.30% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Cumberland Pharmaceuticals, Inc. (CPIX) Director Acquires $22,804.20 in Stock” was reported by Macon Daily and is the sole property of of Macon Daily. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://macondaily.com/2019/04/26/cumberland-pharmaceuticals-inc-cpix-director-acquires-22804-20-in-stock.html.
Cumberland Pharmaceuticals Company Profile
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections.
Read More: What is a support level?
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.